IFNG and hematologic disorder: Most notably, we observed no significant differences in CAR-T efficacy with IFN-γ blockade, and between both systemic (using anti–IFN-γ mAb) and targeted (IFN-γ KO CAR-T) blockade of IFN-γ, which is consistent with findings from a recent study involving hematological malignancies (21).